Unicycive Therapeutics, Inc.
corporate_fare Company Profile
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for UNCY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for UNCY spans 8-K, 10-Q, 144, S-3.
Recent high-impact activity:
- Unicycive Posts $7.0M Q3 Loss, $59M Cash Through 2027 OLC PDUFA
- Unicycive Q3 Loss Widens to $21.5M; $59M Cash Funds Runway Past PDUFA
- FDA Accepts OLC Resubmission, Sets March 25, 2027 PDUFA Date
- Unicycive Resubmits OLC NDA with New Manufacturing Vendor, Adds Commercial Veteran to Board
- Securities Class Action Filed Against Unicycive Over OLC NDA Statements
Financial Snapshot
Short Interest & Short Volume
4.18 days to coverFINRA reported short interest of 4,819,173 shares in UNCY as of the October 30, 2026 settlement, a 1.2% decrease from the prior period — about 4.2 days to cover at its recent average daily volume. On November 19, 2026, 58.2% of UNCY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for UNCY, detected from its recent SEC filings.
ATM Program Expansion · Concurrent S-3 Filing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →